Cosmo Pharmaceuticals Nv · SIX:COPN
Cosmo Pharmaceuticals Nv — Investor Presentation (September 2021)
36 slides from Cosmo Pharmaceuticals Nv's investor presentation, September 2021
Slide 1: Cosmo Delivering Innovation
Cosmo Delivering Innovation September 2021 Cosmo Pharmaceuticals Corporate Presentation September 2021
Slide 2: Safe Harbour
SAFE HARBOUR This presentation may include forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. The inclusion of forward-looking statements should not be regarded as a representation by Cosmo that any of its p
Slide 3: Overview
Overview Cosmo Pharmaceuticals 3 Corporate Presentation September 2021
Slide 4: Cosmo's Expertise
CO S M O ’ S E X P E RT I S E Cosmo has top-class expertise and know-how in three major therapeutic areas • GI • Endoscopy • Dermatology Cosmo Pharmaceuticals 4 Corporate Presentation September 2021
Slide 5: Cosmo Has an Impressive Track Record
CO S M O H A S A N I M P R ES S I V E T R A C K R ECO R D Cosmo’s expertise in these areas has led to: 5 drugs approved by the FDA: Lialda, Uceris, Aemcolo, ByFavo, Winlevi 4 drugs approved by the EU: Mezavant (Lialda), Cortiment (Uceris), RelaFalk (Aemcolo), LuMeBlue Cosmo is the only pharma compan
Slide 6: All Cosmo Products Are One-of-a-Kind and Provide Solutions to Unmet Needs
ALL COSMO PRODUCTS ARE ONE-OF-A-KIND AND PROVIDE SOLUTIONS TO UNMET NEEDS • Lialda - once a day formulation of mesalamine for the treatment of mild Ulcerative Colitis (UC), increasing compliance • Uceris - once a day formulation of budesonide for more severe UC, devoid of side effects • Aemcolo - an
Slide 7: All Cosmo Products Are One-of-a-Kind and Provide Solutions to Unmet Needs
ALL COSMO PRODUCTS ARE ONE-OF-A-KIND AND PROVIDE SOLUTIONS TO UNMET NEEDS • LuMeBlue - first drug to increase detection of lesions during colonoscopies • Eleview - first injectable solution to make polyp removal during colonoscopies safer and faster • GI Genius - first AI based medical device for th
Slide 8: Cosmo's Business Model
COSMO’S BUSINESS MODEL • Cosmo has decided that it will not market its products directly but will pursue partnerships with other companies • All Cosmo’s products are currently partnered with different partners • This enables Cosmo to: - Maintain a lean cost structure - Increase diversification - Red
Slide 9: Current Partnerships
CURRENT PARTNERSHIPS Cosmo Pharmaceuticals 9 Corporate Presentation September 2021
Slide 10: Current Partnerships
CURRENT PARTNERSHIPS Cosmo Pharmaceuticals 10 Corporate Presentation September 2021
Slide 11: Cosmo's Development Pipeline
COSMO’S DEVELOPMENT PIPELINE PRODUCT INDICATION PH I PH II PH III Aemcolo IBS-D Acute Uncomplicated Diverticulitis* Small Intestine BacteriaI Overgrowth (SIBO)* Minimal Hepatic Encephalopathy* Lesion detection during colonoscopy - European Methylene Blue MMX APPROVED Union Methylene Blue MMX Lesion
Slide 12: Cassiopea's (Cosmo's 46.6% Associate) Development Pipeline
CASSIOPEA’S (COSMO’S 46.6% ASSOCIATE) DEVELOPMENT PIPELINE PRODUCT INDICATION PH I PH II PH III Winlevi (clascoterone) cream 1% Acne APPROVED Breezula (clascoterone solution) Male Androgenetic Alopecia Cosmo Pharmaceuticals 12 Corporate Presentation September 2021
Slide 13: Replenishment of Cosmo's Development Pipeline
REPLENISHMENT OF COSMO’S DEVELOPMENT PIPELINE • CB-03-10 for the treatment of solid tumors is now seeing the GMP engineering batches being finalized • The phase I trial with a renewed formulation which significantly increases bio-availability is expected to begin by end 2021 Cosmo Pharmaceuticals 13
Slide 14: Replenishment of Cosmo's Development Pipeline
REPLENISHMENT OF COSMO’S DEVELOPMENT PIPELINE • Cosmo’s is screening for new indications of already approved and off-patent active principles with the help of eminent KOLs • The aim is to: - reduce development risk - shorten the development timeline - increase likelihood of success - streamline the
Slide 15: Replenishment of Cosmo's Development Pipeline
REPLENISHMENT OF COSMO’S DEVELOPMENT PIPELINE • Cosmo is unlikely to take the candidate to Phase 3 as investment would be too great relative to risk without commercial infrastructure • Cosmo is currently focusing on 5 opportunities at early stage and has commenced preliminary feasibility studies Cos
Slide 16: Cosmo's Financial Position
COSMO’S FINANCIAL POSITION Cosmo is an established company with a strong balance sheet and is generating a positive cashflow from operations Market Cap1 Cash, bonds and fund Equity stakes in other CHF 1,218.0 million investments1 companies1 €199.9m €240.3m 2020: €212.9m 2020: €339.2m Treasury shares
Slide 17: Cosmo's HY21 Revenues
COSMO’S HY21 REVENUES Other revenues from sales, 4% Royalties , 9% • HY21 revenue €28.4m vs €25.9m prior year 16 15 H1 2021 Manufacturing generic products, speciality drugs 14 H1 2020 13 and related services, 22% 12 Licence fees , Up-front 10 fees & milestones, 14% 8 6 6 6 4 4 4 2 2 Manufacturing of
Slide 18: Cosmo's Headcount
CO S M O ’ S H EA D CO U N T As at 30th of June 2021 Research and Development 77 28% Production & Logistics 160 58% SG&A 39 14% Total 276 Cosmo has invested heavily in research and development while maintaining a lean organisation structure Overall headcount has increased from 265 at December 2021 a
Slide 19: Cosmo's Stakes in Other Companies as a Result of Partnerships and Spin-offs
CO S M O ’ S S TA K ES I N OT H E R CO M PA N I ES A S A R ES U LT O F PA RT N E RS H I P S A N D S P I N - O F FS • As at 14th of September 2021 the market value of our stakes in other companies, cash, loans, investments and treasury shares was €524.9 million. €M 14 Sep 2021 Shareholding in Cassiop
Slide 20: Recent Milestones
Recent Milestones Cosmo Pharmaceuticals 20 Corporate Presentation September 2021
Slide 21: Recent Milestones
RECENT MILESTONES • Cosmo’s associate, Cassiopea S.p.A. announced it had signed license and supply agreements with Sun Pharmaceutical Industries for Winlevi in US and Canada, July 2021 • GI Genius, the first device that uses artificial intelligence to assist clinicians in the detection lesions in th
Slide 22: Short Term Catalysts
Short Term Catalysts Cosmo Pharmaceuticals 22 Corporate Presentation September 2021
Slide 23: GI Genius
GI GENIUS • In April 2021, GI Genius was approved by the FDA • The FDA assessed the safety and effectiveness of the GI Genius through a multicenter, prospective, randomized, controlled study in Italy with 700 subjects 40-80 years old who were undergoing a colonoscopy for colorectal cancer screening
Slide 24: GI Genius
GI GENIUS The global AI partnership with Medtronic • Now Approved in the US, Europe, Australia, Israel and the United Arab Emirates • Extensive marketing campaign by Medtronic underway • https://www.medtronic.com/us-en/c/digestive-gastrointestinal/gi-genius.html Cosmo Pharmaceuticals 24 Corporate Pr
Slide 25: GI Genius
GI GENIUS Cosmo Pharmaceuticals 25 Corporate Presentation September 2021
Slide 26: GI Genius
GI GENIUS Cosmo Pharmaceuticals 26 Corporate Presentation September 2021
Slide 27: GI Genius
GI GENIUS • We have delivered 262 devices to Medtronic for placement in the US market and 389 for the European Market • Subsequent to the interest shown by the market Medtronic has ordered 3,000 devices, to be delivered in the subsequent months • Cosmo has already manufactured 450 devices which will
Slide 28: Cassiopea SpA
C A S S I O P EA S PA • In July, our associate Cassiopea S.p.A. announced it had signed license and supply agreements with Sun Pharmaceutical Industries for Winlevi in US and Canada • The license agreement is now effective as the parties have received HSR Antitrust Clearance • Cassiopea has received
Slide 29: Aemcolo
AEMCOLO • In January 2021, we announced the successful outcome of our Phase II Proof of Concept (POC) clinical trial of Rifamycin-MMX 600mg in Irritable Bowel Syndrome with Diarrhea (IBS-D) • Together with our licensees, we are commencing discussions with the U.S. and EU regulatory agencies with a v
Slide 30: Methylene Blue MMX
METHYLENE BLUE MMX • In August 2020, the European Commission approved Methylene Blue MMX for the visualization of colorectal lesions during colonoscopies • In December 2020, we licensed the Chinese rights for Lumeblue to China Medical System Holdings Ltd. (“CMS”) (SEHK: 867), approval is expected in
Slide 31: 2021 Key Priorities & Outlook
2021 Key Priorities & Outlook Cosmo Pharmaceuticals 31 Corporate Presentation September 2021
Slide 32: Key Priorities for 2021 and Beyond
KEY PRIORITIES FOR 2021 AND BEYOND • Ensure that GI Genius performs in the US market by providing Medtronic with all the necessary supply and support • Complete the replenishment of our pipeline • Progress the development of Aemcolo in IBS-D • Commence the Methylene Blue MMX confirmatory phase III t
Slide 33: 2021 Guidance
2021 GUIDANCE • Guidance is maintained following FDA approval for GI Genius and assumes an increase in costs associated with the deployment of GI Genius machines to Medtronic and into the market - Revenue in the range of €60m - €64m - Operating profit in the range of €3m - €5m • In addition to the o
Slide 34: Cosmo as Seen by Equity Analysts
COSMO AS SEEN BY EQUITY ANALYSTS • Analyst – Peter Welford • Analyst – Barbora Blaha • BUY Rating • OUTPERFORM Rating • 12 month price target CHF 110 • 12 month price target CHF 95 • Analyst – Paul Verbraeken • Analyst – Bob Pooler • BUY Rating • Risk Adjusted NPV per share CHF 134 • 12 month price
Slide 35: Thank You
Thank You Cosmo Pharmaceuticals 35 Corporate Presentation September 2021
Slide 36: Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. Riverside II Sir John Rogerson’s Quay Dublin 2, Ireland media@cosmopharma.com Mr. Alessandro Della Cha, CEO adellacha@cosmopharma.com Mr. Niall Donnelly, CFO ndonnelly@cosmopharma.com Cosmo Pharmaceuticals 36 Corporate Presentation September 2021
Cosmo Pharmaceuticals — Investor Presentation (September 2021) on 6ix